Incomplete KLK7 Secretion and Upregulated LEKTI Expression Underlie Hyperkeratotic Stratum Corneum in Atopic Dermatitis

详细信息    查看全文

• 作者：Satomi Igawa¹ ; ^{igasato@asahikawa-med.ac.jp} ; Mari Kishibe¹ ; Masako Minami-Hori¹ ; Masaru Honma¹ ; Hisashi Tsujimura² ; Junko Ishikawa³ ; Tsutomu Fujimura³ ; Masamoto Murakami⁴ ; Akemi Ishida-Yamamoto¹
• 关键词：AD ; atopic dermatitis ; CD ; corneodesmosome ; Cdsn ; corneodesmosin ; KLK ; kallikrein-related peptidase ; LEKTI ; lymphoepithelial Kazal-type-related inhibitor ; LG ; lamellar granule ; NS ; Netherton syndrome ; SC ; stratum corneum
• 刊名：Journal of Investigative Dermatology
• 出版年：2017
• 出版时间：February 2017
• 年：2017
• 卷：137
• 期：2
• 页码：449-456
• 全文大小：2291 K
• 卷排序：137

文摘

Atopic dermatitis (AD) is a common inflammatory skin disorder. Chronic AD lesions present hyperkeratosis, indicating a disturbed desquamation process. KLK7 is a serine protease involved in the proteolysis of extracellular corneodesmosome components, including desmocollin 1 and corneodesmosin, which leads to desquamation. KLK7 is secreted by lamellar granules and upregulated in AD lesional skin. However, despite increased KLK7 protein levels, immunostaining and electron microscopy indicated numerous corneodesmosomes remaining in the uppermost layer of the stratum corneum from AD lesions. We aimed to clarify the discrepancy between KLK7 overexpression and retention of corneodesmosomes on AD corneocytes. Western blot analysis indicated abnormal corneodesmosin degradation patterns in stratum corneum from AD lesions. The KLK activity of tape-stripped corneocytes from AD lesions was not significantly elevated in in situ zymography, which was our new attempt to detect the protease activity more precisely than conventional assays. This ineffective KLK activation was associated with impaired KLK7 secretion from lamellar granules and increased expression of LEKTI in AD. Such imbalances in protease-protease inhibitor interactions could lead to abnormal proteolysis of corneodesmosomes and compact hyperkeratosis. Upregulated expression of LEKTI might be a compensatory mechanism to prevent further barrier dysfunction in AD.